Airat Bilyalov

Dr. Airat Bilyalov

Kazan Federal University, Kazan’, Russia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in Genes & Cells
Verified
Journal Article
Closed access
RDR. V Deev
R. V Deev
Airat BilyalovAirat Bilyalov
Airat Bilyalov
TZT. M Zhampeisov
T. M Zhampeisov
Cell death is an important part of normal (physiological) and pathological histogenesis. In the past two decades, our knowledge of the processes of non-programmed and programmed cell death significantly enriched. The International Nomenclature Committee on Cell Death is constantly working, it regularly updates information on the terminology and development mechanisms recommended for this or that type of death, but the general principle of classification of cell death has not yet been worked out. In this review, the principle of separation according to which the mechanisms involved in physiological histogenesis include the rooting, the external pathway of apoptosis, anoikis, macroautophagy and lysosome-dependent cell death. The mechanisms involved in pathological histogenesis include: the internal pathway of apoptosis, necroptosis, pyroptosis, netosis, mitotic catastrophe, partanatosis, entosis, mitochondrial-driven necrosis, ferroptosis, immunogenic cell death, necrosis and oncosis.

18 December 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
ADAnastasiia Danishevich
Anastasiia Danishevich
Airat BilyalovAirat Bilyalov
Airat Bilyalov
SNSergey Nikolaev
Sergey Nikolaev
NKNodirbek Khalikov
Nodirbek Khalikov
ДИДарья Исаева
Дарья Исаева
NBNatalia Bodunova
Natalia Bodunova
Malignant neoplasms, including pancreatic cancer and melanoma, are major global health challenges. This study investigates melanoma pancreatic syndrome, a rare hereditary tumor syndrome associated with CDKN2A gene mutations. CDKN2A mutations contribute to a lifetime risk of melanoma ranging from 28% to 67%. This study reports the clinical features of six individuals with CDKN2A mutations and identifies recurrent alterations such as c.307_308del, c.159G>C and c.71G>C. It highlights the need for CDKN2A mutation testing in suspected cases of familial atypical multiple mole melanoma. Clinically significant variants show associations with melanoma and pancreatic cancer. The challenges of treating individuals with CDKN2A mutations are discussed, and the lack of specific targeted therapies is highlighted. Preclinical studies suggest a potential benefit of CDK4/6 inhibitors, although clinical trials show mixed results. This study underscores the importance of continued research into improved diagnostic and therapeutic strategies to address the complexities of hereditary cancer syndromes.

Verified
Journal Article
Open access
PDF file
ATAngelina Titova
Angelina Titova
SNSergey Nikolaev
Sergey Nikolaev
Airat BilyalovAirat Bilyalov
Airat Bilyalov
NFNikita Filatov
Nikita Filatov
SBSergei Brovkin
Sergei Brovkin
OGOleg Gusev
Oleg Gusev
The extraocular muscles (EOMs) possess unique characteristics that set them apart from other skeletal muscles. These muscles, responsible for eye movements, exhibit remarkable resistance to various muscular dystrophies and aging, presenting a significant contrast to the vulnerability of skeletal muscles to these conditions. In this review, we delve into the cellular and molecular underpinnings of the distinct properties of EOMs. We explore their structural complexity, highlighting differences in fiber types, innervation patterns, and developmental origins. Notably, EOM fibers express a diverse array of myosin heavy-chain isoforms, retaining embryonic forms into adulthood. Moreover, their motor innervation is characterized by a high ratio of nerve fibers to muscle fibers and the presence of unique neuromuscular junctions. These features contribute to the specialized functions of EOMs, including rapid and precise eye movements. Understanding the mechanisms behind the resilience of EOMs to disease and aging may offer insights into potential therapeutic strategies for treating muscular dystrophies and myopathies affecting other skeletal muscles.

11 August 2025 in Genes
Verified
Journal Article
Open access
PDF file
ATAngelina Titova
Angelina Titova
Airat BilyalovAirat Bilyalov
Airat Bilyalov
NFNikita Filatov
Nikita Filatov
SPStepan Perepechenov
Stepan Perepechenov
DKDarya Kupriyanova
Darya Kupriyanova
OGOleg Gusev
Oleg Gusev
Sarcopenia, the progressive loss of skeletal muscle mass and function with age, significantly contributes to frailty and mortality in older adults. Notably, muscles do not age uniformly—some retain structure and strength well into old age. This review explores the mechanisms underlying differential resistance to muscle aging, with a focus on sarcopenia-resistant muscles. We analyzed current literature across molecular biology, genetics, and physiology to identify key regulators of muscle preservation during aging. Special attention was given to muscle fiber types, mitochondrial function, neuromuscular junctions, and satellite cell activity. Muscles dominated by slow-twitch (type I) fibers—such as the soleus, diaphragm, and extraocular muscles—demonstrate enhanced resistance to sarcopenia. This resilience is linked to sustained oxidative metabolism, high mitochondrial density, robust antioxidant defenses, and preserved regenerative capacity. Key molecular pathways include mTOR, PGC-1α, and SIRT1/6, while genetic variants in ACTN3, MSTN, and FOXO3 contribute to interindividual differences. In contrast, fast-twitch muscles are more vulnerable due to lower oxidative capacity and satellite cell depletion. Unique innervation patterns and neurotrophic support further protect muscles like extraocular muscles from age-related atrophy. Resistance to sarcopenia is driven by a complex interplay of intrinsic and extrinsic factors. Understanding why specific muscles age more slowly provides insights into muscle resilience and suggests novel strategies for targeted prevention and therapy. Expanding research beyond traditionally studied muscles is essential to develop comprehensive interventions to preserve mobility and independence in aging populations.

Verified
Journal Article
Open access
PDF file
DKDarya Kupriyanova
Darya Kupriyanova
Airat BilyalovAirat Bilyalov
Airat Bilyalov
NFNikita Filatov
Nikita Filatov
SBSergei Brovkin
Sergei Brovkin
DSDmitrii Shestakov
Dmitrii Shestakov
OGOleg Gusev
Oleg Gusev
Sarcopenia is a progressive loss of skeletal muscle mass and strength with major clinical and economic consequences. While traditional models emphasize mitochondrial dysfunction, inflammation, and proteostasis imbalance, emerging data highlight a neurogenic component involving motor neuron loss, fiber denervation, neuromuscular junction remodeling, and disrupted trophic signaling. To synthesize current evidence on neurogenic mechanisms of sarcopenia revealed by next-generation sequencing and related multi-omics, to map molecular networks across cell types, and to outline translational opportunities for diagnostics and targeted therapy. A narrative review of human and animal studies indexed in PubMed, Web of Science, and Scopus through November 2025. Search terms combined sarcopenia, denervation, neuromuscular junction, neurotrophic signaling, genomics, transcriptomics, epigenomics, single-cell, and spatial transcriptomics. Eligible studies reported omics or physiological endpoints related to neuromuscular function. Convergent omics data support a central role of the nervous system in the onset and progression of sarcopenia. Genetic and regulatory factors linked to denervation, transcriptomic signatures of junctional disassembly, and cell-specific dysfunctions in motor neurons, Schwann cells, satellite cells, and fibro-adipogenic progenitors have been identified. Epigenetic and transcriptional networks underlying neuromuscular homeostasis, along with candidate circulating biomarkers, provide targets for clinical translation. Neurogenic sarcopenia represents a tractable target for precision prevention and therapy. Integration of multi-omics, artificial intelligence, and advanced models such as innervated organoids and NMJ-on-chip systems can accelerate target validation and enable personalized strategies to preserve neuromuscular function.

21 May 2020 in BioNanoScience
Verified
Journal Article
Closed access
PDF file
Airat BilyalovAirat Bilyalov
Airat Bilyalov
NSNasrulla Shanazarov
Nasrulla Shanazarov
SZS. V. Zinchenko
S. V. Zinchenko